Filippo Pietrantonio

Fondazione IRCCS Istituto Nazionale dei Tumori

Publishes on Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Genetic factors in colorectal cancer. 1k papers and 16.9k citations.

PubIndex Score98Top 2%How it's scored

1kPublications

16.9kTotal Citations

First publication: 1990First senior author: 2013

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Genetic factors in colorectal cancer Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers

Top publicationsby citations

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Santini, Francesca Bergamo et al.|JAMA Oncology|2018

Cited by 418

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Filippo Pietrantonio, Vincenzo Guarini et al.|British Journal of Cancer|2020

Cited by 350

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020

Cited by 322

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Chiara Cremolini, Daniele Rossini et al.|The Lancet Oncology|2022

Cited by 268

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022

Cited by 259